Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Graham

Showing results (1311-1320 of 1,460) with videos related to

Pageof 146
Sort By:
Journal of AIDS & Clinical Research|November 21, 2015
Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive IndividualsJonathan D Fuchs, Pierre-Alexandre Bart, Nicole Frahm, et al.
The Journal of Infectious Diseases|May 21, 1998
Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation GroupM L Clements-Mann, K Weinhold, T J Matthews, et al.
Elife|August 5, 2020
Tailored design of protein nanoparticle scaffolds for multivalent presentation of viral glycoprotein antigensGeorge Ueda, Aleksandar Antanasijevic, Jorge A Fallas, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 29, 2021
Anxiety and depression symptoms after COVID-19 infection: results from the COVID Symptom Study appKerstin Klaser, Ellen J Thompson, Long H Nguyen, et al.
The Lancet. Infectious Diseases|January 5, 2016
Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a studyOlga De Santis, Régine Audran, Emilie Pothin, et al.
Lancet (London, England)|December 27, 2014
Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trialHannah Kibuuka, Nina M Berkowitz, Monica Millard, et al.
The Lancet. Digital Health|July 26, 2021
Anosmia, ageusia, and other COVID-19-like symptoms in association with a positive SARS-CoV-2 test, across six national digital surveillance platforms: an observational studyCarole H Sudre, Ayya Keshet, Mark S Graham, et al.
Science (New York, N.Y.)|March 24, 2022
Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529Tongqing Zhou, Lingshu Wang, John Misasi, et al.
Biorxiv : the Preprint Server for Biology|May 5, 2021
A broadly neutralizing antibody protects against SARS-CoV, pre-emergent bat CoVs, and SARS-CoV-2 variants in miceDavid R Martinez, Alexandra Schaefer, Sophie Gobeil, et al.
Nature Communications|February 2, 2022
Self-reported COVID-19 vaccine hesitancy and uptake among participants from different racial and ethnic groups in the United States and United KingdomLong H Nguyen, Amit D Joshi, David A Drew, et al.
Pageof 146

Showing results (1311-1320 of 1,460) with videos related to

Sort By:
Pageof 146
Journal of AIDS & Clinical Research|November 21, 2015
Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive IndividualsJonathan D Fuchs, Pierre-Alexandre Bart, Nicole Frahm, et al.
The Journal of Infectious Diseases|May 21, 1998
Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation GroupM L Clements-Mann, K Weinhold, T J Matthews, et al.
Elife|August 5, 2020
Tailored design of protein nanoparticle scaffolds for multivalent presentation of viral glycoprotein antigensGeorge Ueda, Aleksandar Antanasijevic, Jorge A Fallas, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 29, 2021
Anxiety and depression symptoms after COVID-19 infection: results from the COVID Symptom Study appKerstin Klaser, Ellen J Thompson, Long H Nguyen, et al.
The Lancet. Infectious Diseases|January 5, 2016
Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a studyOlga De Santis, Régine Audran, Emilie Pothin, et al.
Lancet (London, England)|December 27, 2014
Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trialHannah Kibuuka, Nina M Berkowitz, Monica Millard, et al.
The Lancet. Digital Health|July 26, 2021
Anosmia, ageusia, and other COVID-19-like symptoms in association with a positive SARS-CoV-2 test, across six national digital surveillance platforms: an observational studyCarole H Sudre, Ayya Keshet, Mark S Graham, et al.
Science (New York, N.Y.)|March 24, 2022
Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529Tongqing Zhou, Lingshu Wang, John Misasi, et al.
Biorxiv : the Preprint Server for Biology|May 5, 2021
A broadly neutralizing antibody protects against SARS-CoV, pre-emergent bat CoVs, and SARS-CoV-2 variants in miceDavid R Martinez, Alexandra Schaefer, Sophie Gobeil, et al.
Nature Communications|February 2, 2022
Self-reported COVID-19 vaccine hesitancy and uptake among participants from different racial and ethnic groups in the United States and United KingdomLong H Nguyen, Amit D Joshi, David A Drew, et al.
Pageof 146